Effexor, Celexa subpoenas
Executive Summary
U.S. Office of Personnel Management issues request for documents related to marketing and promotional practices for psychopharmacologic drugs, including Wyeth's Effexor and Forest's Celexa. OPM's Inspector General also recently issued a request for documents related to Johnson & Johnson's antipsychotic Risperdal (risperidone) (1"The Pink Sheet" Jan. 26, 2004, In Brief) [For more coverage of the subpoenas, visit 2"The Pink Sheet" Daily]...
You may also be interested in...
Zyprexa investigation possible
Lilly antipsychotic Zyprexa (risperidone) may be next mental health product subject to an U.S. Office of Personnel Management investigation. "Several pharmaceutical companies have received subpoenas from government agencies with respect to a variety of products, including a number of neuroscience products," 1Lilly's 8-K, filed with the Securities & Exchange Commission March 9, says. "It is possible that other Lilly products, including Zyprexa, could become subject to investigation." OPM has issued requests related to Wyeth's Effexor, Forest's Celexa and Johnson & Johnson's Risperdal (2"The Pink Sheet" Feb. 2, 2004, In Brief)...
J&J Risperdal subpoena
Johnson & Johnson receives subpoena from HHS Office of the Inspector General for documents relating to the atypical antipsychotic Risperdal (risperidone). Boston U.S. Attorney's Office is investigating J&J's sales and marketing practices for the anti-epileptic Topamax (topiramate) (1"The Pink Sheet" Dec. 15, 2003, In Brief). Both products are widely used off-label...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.